Funding for this research was provided by:
Received: 8 June 2019
Accepted: 30 September 2020
First Online: 17 October 2020
Ethics approval and consent to participate
: This study was approved by the University of New England Independent Review Board for the Protection of Human Subjects in Research (012616–019). All subjects gave written informed consent.
: Form Attached. This manuscript has not been previously published and is not under consideration in any other peer-reviewed media.
: NC has received consulting fees and research contracts from various entities through her contract research organization, Five Islands Consulting, LLC. Her paid and unpaid research and consulting have included developing and/or evaluating shared decision-making tools for multiple sclerosis (MS), aortic stenosis, atrial fibrillation, chronic pain, sleep apnea, and neurocritical care. Paid consulting included advising Miami University (assessing the quality of medical information), Biogen through their MS Quality Steering Committee, Emmi Solutions in developing decision aids, Wolters Kluwer in updating decision aids, Janssen Scientific Affairs, LLC (training, decision aids), 3D Communications (consulting), Epi-Q (consulting), Synchrony Group (consulting), Mallinckrodt’s SpecGx LLC (one-time consulting fee and reimbursement of travel), AceRx (one-time consulting fee and reimbursement of travel), Pacific Northwest University (travel expenses and honoraria), EMD-Serono (travel expenses, speaker fees, and research funding), and Edwards Lifesciences (research funding).She serves as an unpaid mentor for 2 NIH training (K) grants developing decision tools in the areas of sleep apnea and neurocritical care. She received an independent research grant from MSAA (Multiple Sclerosis Association of America), Pfizer (in the area of chronic pain) and a research grant from Biogen (in the area of MS). She has 2 research grants under consideration: the Association of Community Cancer Centers (ACCC) and EMD Serono.These authors declare that they have no competing interests: LN, VS, BT, NG, RE, EM, FS, SG, SH, NN, LP, MS.